Osteoarthritis Gene Therapy: A 30‐Year Journey From Concept to Clinical Trials
Journal of Orthopaedic Research · 2026
DOI: 10.1002/jor.70141 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Orthopaedic Research, 2026. Verfasst von Christopher H Evans und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Physical Medicine & Rehabilitation, Orthopaedic Surgery, and Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Osteoarthritis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: NIH HHS, DoD, Mayo Clinic Transform the Practice Program.
Abstract (Originalsprache)
This manuscript summarizes over 30 years of research that began with the novel concept of using intra‐articular gene transfer to treat joint diseases. A notable milestone in this journey was the first‐in‐human transfer of an exogenous gene to a joint, accomplished by the ex vivo delivery of cDNA encoding the interleukin‐1 receptor antagonist (IL‐1Ra) to joints of patients with rheumatoid arthritis. Responding to lessons learned from this study and the prevailing clinical landscape we next developed an in vivo gene delivery system based on adeno‐associated virus (AAV) with osteoarthritis (OA) as the target disease. The safety and efficacy of this vector, sc‐rAAV2.5IL‐1Ra, was demonstrated in the joints of rats and horses leading to a successful IND application to the FDA. In this clinical trial (ClinicalTrials. gov Identifier: NCT02790723) sc‐rAAV2.5IL‐1Ra was injected at escalating doses into the knee joints of nine patients with OA who were followed for 1 year. This trial met its primary outcome measure, safety, and demonstrated that sustained expression of transgenic IL‐1Ra was possible after a single injection of the vector. Patient‐reported outcomes improved, but without a control group it is not possible to determine the influence of a placebo effect. This and other unresolved matters are addressed in a recently‐completed Phase Ib trial (ClinicalTrials. gov Identifier: NCT05835895). Beyond OA, sc‐rAAV2.5IL‐1Ra has potential therapeutic value in a variety of degenerative, inflammatory, fibrotic and autoimmune conditions. More generally, gene therapy holds much promise in the field of regenerative medicine, including regenerative orthopaedics. Trial Registration: (ClinicalTrials. gov Identifier: NCT02790723, NCT05835895).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Physical Medicine & Rehabilitation, Orthopaedic Surgery, and Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Orthopedics and Rehabilitation, University of Florida College of Medicine, Gainesville, Florida, USA.
- Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Förderung
- NIH HHS
- DoD
- Mayo Clinic Transform the Practice Program
- California Institute of Regenerative Medicine
- NIH
Zitieren
APA
Evans, C. H., Ghivizzani, S. C., & Robbins, P. D. (2026). Osteoarthritis Gene Therapy: A 30‐Year Journey From Concept to Clinical Trials. Journal of Orthopaedic Research. https://doi.org/10.1002/jor.70141
Vancouver
Evans CH, Ghivizzani SC, Robbins PD. Osteoarthritis Gene Therapy: A 30‐Year Journey From Concept to Clinical Trials. Journal of Orthopaedic Research. 2026. doi:10.1002/jor.70141
BibTeX
@article{Evans2026,
author = {Evans, Christopher H and Ghivizzani, Steven C and Robbins, Paul D},
title = {Osteoarthritis Gene Therapy: A 30‐Year Journey From Concept to Clinical Trials},
journal = {Journal of Orthopaedic Research},
year = {2026},
doi = {10.1002/jor.70141}
}
EUVIMED